Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Optimoz
- Development stage
- Unknown
- Lead developer
- Jay Ell Healthcare
- Administration
- Oral
01
Overview
**Optimoz** is an orange-flavored chewable nutraceutical tablet developed and marketed by Jay Ell Healthcare for polycystic ovary syndrome, anovulation, hyperandrogenism, irregular menstrual cycles, acne, and hirsutism. Each tablet contains myo-inositol 550 mg, D-chiro-inositol 13.8 mg in a 40:1 ratio, chromium picolinate 100 mcg, and vitamin D2 200 IU. It is intended to provide nutritional and metabolic support in PCOS, including support for insulin sensitivity and hormonal balance; it is described by the manufacturer for patients with body mass index below 25. ([jayellhealthcare.com](https://jayellhealthcare.com/2019/11/20/optimoz/))
- Brand names
- Optimoz
02
Targets
VDR (Vitamin D receptor)INSR (Insulin receptor)
Beyond the preview
Go deeper on Optimoz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optimoz.